David Shotlander

10 Years After Actavis, The Cases That Follow Tell A Story

D.C. Circuit Dismisses FTC Antitrust Suit: Exclusive Pharma Patent Licenses Remain Permissible Under The Patent Act

SEP Enforcement: Has The Biden Administration Tabled A Revised Policy Statement?

Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of "Profit Crushing Competition"

The Sham Litigation Exception After AbbVie - Is The Subjective Element A Sham?

FDA Acting Commissioner Of Food And Drugs Seeks Collaboration Between FDA And USPTO To Address Pharmaceutical Patent-Related Matters Affecting Competition

Federal Circuit Clarifies The Scope Of Its Jurisdiction Over Walker Process Antitrust Claims In Chandler. v. Phoenix Services LLC

Can Biologics Manufacturers Face Antitrust Risk For Pointing Out That Biosimilars Are Different?

FDA And FTC To Scrutinize Biologics Competition

Pharmaceutical Antitrust Update: Courts Address How And When Product Hopping May Violate The Antirust Laws